Michael Hoelscher Selected Research

Duration of Therapy

1/2021	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
1/2021	Optimising pyrazinamide for the treatment of tuberculosis.
1/2021	Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
1/2018	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
4/2016	Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
3/2015	Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.
4/2014	New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
1/2012	Advancing the development of tuberculosis therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Hoelscher Research Topics

Disease

37	Tuberculosis (Tuberculoses) 02/2023 - 12/2008
29	Infections 03/2024 - 10/2002
10	HIV Infections (HIV Infection) 06/2023 - 12/2010
9	COVID-19 02/2024 - 01/2021
5	Pulmonary Tuberculosis 01/2018 - 08/2009
3	Breakthrough Infections 07/2023 - 01/2021
3	Filarial Elephantiasis (Lymphatic Filariasis) 01/2022 - 04/2016
3	Spotted Fever Group Rickettsiosis (Rickettsialpox) 01/2021 - 01/2014
3	Viremia 01/2021 - 03/2007
3	Disease Progression 06/2020 - 11/2010
3	Malaria 06/2018 - 01/2007
3	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 03/2015 - 01/2013
2	Inflammation (Inflammations) 02/2024 - 01/2022
2	Imported Communicable Diseases 10/2016 - 01/2016
2	Coinfection 08/2016 - 04/2016
2	Noncommunicable Diseases 04/2016 - 05/2012
2	Communicable Diseases (Infectious Diseases) 04/2016 - 01/2016
2	Proteinuria 09/2015 - 08/2009
2	Acquired Immunodeficiency Syndrome (AIDS) 05/2015 - 12/2008
1	Dengue (Dengue Fever) 02/2024
1	Yellow Fever 02/2024
1	Neoplasms (Cancer) 08/2023
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2023
1	Virus Diseases (Viral Diseases) 01/2023
1	Chronic Disease (Chronic Diseases) 01/2023
1	Latent Tuberculosis 07/2022
1	West Nile Fever 01/2022
1	Meningitis 01/2022
1	Hepatitis B 01/2021
1	Epidemic Louse-Borne Typhus (Typhus) 01/2021
1	Hepatitis C 01/2021
1	Severe Acute Respiratory Syndrome 01/2020
1	Intestinal Volvulus (Volvulus) 10/2017
1	Malnutrition (Nutritional Deficiencies) 07/2016
1	Lung Injury 04/2016
1	Meningeal Tuberculosis (Tuberculous Meningitis) 01/2016

Drug/Important Bio-Agent (IBA)

17	AntibodiesIBA 03/2024 - 01/2014
11	VaccinesIBA 02/2024 - 10/2002
9	Rifampin (Rifampicin)FDA LinkGeneric 01/2021 - 09/2010
8	Immunoglobulin G (IgG)IBA 02/2024 - 01/2014
7	Biomarkers (Surrogate Marker)IBA 06/2023 - 01/2011
7	AntigensIBA 02/2023 - 03/2012
6	lipoarabinomannan (LAM)IBA 03/2016 - 08/2009
5	Immunoglobulin M (IgM)IBA 01/2022 - 01/2016
5	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 12/2010
4	Albendazole (Albenza)FDA Link 01/2022 - 03/2014
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 12/2008
4	Tuberculin (PPD)IBA 01/2018 - 12/2008
3	EpitopesIBA 02/2024 - 03/2007
3	Anti-Bacterial Agents (Antibiotics)IBA 02/2023 - 01/2021
3	Indicators and Reagents (Reagents)IBA 01/2023 - 01/2022
3	Ivermectin (Mectizan)FDA Link 01/2022 - 04/2016
3	Interferon-gamma (Interferon, gamma)IBA 01/2021 - 12/2008
3	Drug CombinationsIBA 01/2019 - 05/2012
2	Yellow Fever Vaccine (Vaccine, Yellow Fever)FDA Link 02/2024 - 01/2023
2	CytokinesIBA 02/2024 - 12/2008
2	COVID-19 VaccinesIBA 11/2023 - 01/2022
2	AIDS VaccinesIBA 11/2023 - 04/2011
2	C-Reactive ProteinIBA 01/2022 - 10/2016
2	Cholera ToxinIBA 05/2021 - 01/2016
2	Pyrazinamide FDA LinkGeneric 01/2021 - 01/2017
2	Nucleic AcidsIBA 01/2019 - 01/2019
2	Isoniazid (Ftivazide)FDA LinkGeneric 01/2017 - 09/2010
2	Moxifloxacin (Avelox)FDA Link 01/2017 - 03/2015
2	Interleukin-2 (IL2)IBA 10/2016 - 12/2010
2	GoldIBA 04/2013 - 01/2012
1	ChemokinesIBA 02/2024
1	platelet-derived growth factor AIBA 02/2024
1	flt3 ligand protein (flt3 ligand)IBA 02/2024
1	Epidermal Growth Factor (EGF)IBA 02/2024
1	Chemokine CCL5IBA 02/2024
1	ChitinasesIBA 02/2023
1	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2023
1	thiamine triphosphorate (TTP)IBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2022
1	N 30IBA 01/2022
1	InterferonsIBA 01/2022
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	Hepatitis delta Antigens (HDAg)IBA 01/2021
1	BNT162 VaccineIBA 01/2021
1	Virus ReceptorsIBA 01/2020
1	Viral RNAIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2019
1	artemisinin (artemisinine)IBA 06/2018
1	Ethambutol (Myambutol)FDA LinkGeneric 01/2017
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 10/2016
1	Monoclonal AntibodiesIBA 04/2016
1	Immunomodulating AgentsIBA 04/2016
1	Immunoglobulin A (IgA)IBA 01/2016
1	EnzymesIBA 01/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2016
1	TransferasesIBA 01/2016
1	Alanine Transaminase (SGPT)IBA 01/2016
1	Neutralizing AntibodiesIBA 05/2015

Therapy/Procedure

11	Therapeutics 01/2022 - 01/2012
8	Duration of Therapy 01/2021 - 01/2012
4	Aftercare (After-Treatment) 03/2014 - 09/2005
1	Long-Term Care 02/2024
1	Home Nursing (Nursing, Home) 02/2024
1	Immunomodulation 01/2022